Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019
BURLINGTON, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as Kellgren-Lawrence (KL) Grades 2-4 >80% of KL Grade 4 patients entering the trial with moderate to severe knee pain subsequently
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , July 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to ten new employees consisting of an aggregate of 29,050 stock options and 5,350 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year
Only Boston-area biopharmaceutical company recognized in medium business category BURLINGTON, Mass. , June 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the third consecutive
View HTML
Toggle Summary Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
BURLINGTON, Mass. , June 18, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO Capital Markets 2019 Prescriptions for Success Healthcare
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , June 07, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 10 new employees consisting of an aggregate of 25,250 stock options and 4,350 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis
BURLINGTON, Mass. , June 05, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645 for FX201, the company's gene therapy product candidate.
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
BURLINGTON, Mass. , May 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2019 RBC Capital Markets Global Healthcare Conference in New York
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Pooled analysis published in Pain and Therapy indicated that the number of rescue medication tablets used per day through Week 24 was significantly less for ZILRETTA versus placebo and triamcinolone acetonide crystalline suspension (TAcs) Reduced rescue medication use further supports the analgesic
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  ( triamcinolone acetonide extended-release injectable suspension) net sales of $10.6 million in first quarter 2019 Preliminary ZILRETTA net sales for April 2019 were approximately $5.1 million   Flexion reaffirms full-year 2019 revenue guidance of $65-$80 million  
View HTML